Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report

Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline

(2018) A.J. Ullmann et al.   CLINICAL MICROBIOLOGY AND INFECTION

Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients

(2018) Assaf A. Barg et al.   PEDIATRIC BLOOD & CANCER

Isavuconazole in a Successful Combination Treatment of Disseminated Mucormycosis in a Child with Acute Lymphoblastic Leukaemia and Generalized Haemochromatosis: A Case Report and Review of the Literature

(2018) Anna Pomorska et al.   MYCOPATHOLOGIA

New pharmacological opportunities for the treatment of invasive mould diseases

(2017) Marie-Pierre Ledoux et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Invasive mucormycosis in children: an epidemiologic study in European and non-European countries based on two registries

(2016) Zoi Dorothea Pana et al.   BMC INFECTIOUS DISEASES

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

(2016) Frederic Tissot et al.   HAEMATOLOGICA

Mucormycoses

(2016) Dimitrios Farmakiotis et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review

(2016) T. Jancel et al.   JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial

(2016) Johan A Maertens et al.   LANCET

Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis

(2016) Francisco M Marty et al.   LANCET INFECTIOUS DISEASES

ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients

(2016) Frederic Tissot et al.   HAEMATOLOGICA

Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis

(2015) F. Lanternier et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Epidemiology of mucormycosis in Europe

(2014) G. Petrikkos et al.   CLINICAL MICROBIOLOGY AND INFECTION

ESCMID† and ECMM‡ joint clinical guidelines for the diagnosis and management of mucormycosis 2013

(2014) O.A. Cornely et al.   CLINICAL MICROBIOLOGY AND INFECTION

Tissue Penetration of Antifungal Agents

(2014) T. Felton et al.   CLINICAL MICROBIOLOGY REVIEWS

Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation

(2014) Andreas H Groll et al.   LANCET ONCOLOGY

A Global Analysis of Mucormycosis in France: The RetroZygo Study (2005-2007)

(2012) F. Lanternier et al.   CLINICAL INFECTIOUS DISEASES

Zygomycosis in Europe: analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007

(2011) A. Skiada et al.   CLINICAL MICROBIOLOGY AND INFECTION